REFERENCES:
1. Roger VL, Go AS,
Lloyd-Jones DM, et al. Executive summary: heart disease and stroke
statistics-2012 update: a report from the American Heart Association.Circulation. 2012;125(1):188-197.
2. Yusuf S, Rangarajan S, Teo
K, et al. Cardiovascular risk and events in 17 low-, middle-, and
high-income countries. New England Journal of Medicine.2014;371(9):818-827.
3. Fawzy MS, Toraih EA, Aly
NM, Fakhr-Eldeen A, Badran DI, Hussein MH. Atherosclerotic and
thrombotic genetic and environmental determinants in Egyptian coronary
artery disease patients: a pilot study. BMC Cardiovascular
Disorders. January 13 2017;17(1):26.
4. Morrow DA, Lemos JAd,
Sabatine MS, et al. Clinical Relevance of C-Reactive Protein During
Follow-Up of Patients With Acute Coronary Syndromes in the
Aggrastat-to-Zocor Trial. Circulation. 2006;114(4):281-288.
5. Koenig W. High-sensitivity
C-reactive protein and atherosclerotic disease: From improved risk
prediction to risk-guided therapy. International Journal of
Cardiology. 2013;168(6):5126-5134.
6. Ridker PM. A Test in
Context: High-Sensitivity C-Reactive Protein. Journal of the
American College of Cardiology. 2016/02/16/ 2016;67(6):712-723.
7. Silva D, Pais de Lacerda
A. High-sensitivity C-reactive protein as a biomarker of risk in
coronary artery disease. Revista Portuguesa de Cardiologia
(English Edition). 2012/11/01/ 2012;31(11):733-745.
8. Amsterdam EA, Wenger NK,
Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients
With Non–ST-Elevation Acute Coronary Syndromes. J Am Coll
Cardiol. 2014;64(24):e139-e228.
9. Jamshidpour B, Moghadam
BA, Vasaghi-Gharamaleki B, Mirzaii-Dizgah I, Nejatian M. The effects of
phase III cardiac rehabilitation in serum and salivary Hs-CRP and
anthropometric measurements in patients with coronary artery disease.J Contemp Dent Pract. 2013;14(5):819-824.
10. Milfred-LaForest SK,
Chow SL, DiDomenico RJ, et al. Clinical Pharmacy Services in Heart
Failure: An Opinion Paper From the Heart Failure Society of America and
American College of Clinical Pharmacy Cardiology Practice and Research
Network. Journal of cardiac failure. 2013;19(5):354-369.
11. Casper EA, El Wakeel LM,
Saleh MA, El-Hamamsy MH. Management of pharmacotherapy-related problems
in acute coronary syndrome: role of clinical pharmacist in cardiac
rehabilitation unit. Basic & Clinical Pharmacology &
Toxicology. 2019;0(ja).
Table 1. Medications Administered by both Groups at baseline and After 3
months.